Madrigal Pharmaceuticals - Rising Sales of Rezdiffra Drive Momentum!
Reading Time: 1 minute
Business drivers: Madrigal Pharmaceuticals is a U.S. biopharmaceutical company specializing in therapies for the treatment of MASH. With Rezdiffra (Resmetirom), it has the first FDA-approved medication for this liver disease since 2024, with Rezdiffra generating over $200 million in revenue in Q2 2025. On August 12, UBS reaffirmed its rating of Buy and raised its price target from $458 to $523.
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
